Drug intelligence / Profile preview

STP369

Development stage: Discontinued
Lead developer: Sirnaomics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Intratumoral, Subcutaneous, Intradermal, Systemic

Overview

STP369 is a dual-targeting RNA interference (RNAi) therapeutic candidate initially developed by Sirnaomics. It is designed to simultaneously inhibit the expression of two key anti-apoptotic proteins: **Bcl-xl** (Apoptosis regulator Bcl-X) and **Mcl-1** (Induced myeloid leukemia cell differentiation protein). By utilizing small interfering RNA (siRNA) to silence these pro-survival factors, the drug aims to restore the natural apoptotic pathways in cancer cells, particularly those that have developed resistance to standard treatments. The development of STP369 has been discontinued.

Targets

BCL2L1 (B-cell lymphoma-extra large protein)MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on STP369.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STP369.

Explore the full profile